MRC Clinical Trials Unit at UCL
LightNews LightNews
banner
mrcctu.bsky.social
MRC Clinical Trials Unit at UCL
@mrcctu.bsky.social
1K followers 280 following 340 posts
We carry out innovative #ClinicalTrials and develop new #Methodology that has global impact, improving health worldwide.

#MedSky #StatsSky
Posts Replies Media Videos
mrcctu.bsky.social
📺 Catch this short film on the ARCHERY study by LSHTM (@lshtm.bsky.social), where Dr. Ajay Aggarwal explores how AI could improve access to radiotherapy.

A powerful look at tech-driven solutions to global cancer care challenges.

🔗 www.youtube.com/watch?v=lTox...

#Radiotherapy #GlobalHealth
AI in Radiotherapy: A revolution in cancer care?
YouTube video by LSHTM
www.youtube.com
November 11, 2025 at 2:04 PM
mrcctu.bsky.social
Wednesday already? Let’s celebrate another #ProudestOf moment from our brilliant team at the Unit!

This week, we’re spotlighting Ilaria Motta, one of our passionate Principal Clinical Research Fellows working on tuberculosis #TB.

We asked Ilaria what she’s #ProudestOf in her work at the Unit👇
A card with a quote from Ilaria Motta. It reads “The thing I’m proudest of from working in our Unit is the incredible motivation and teamwork that drive the PARADIGM4TB trial. It’s an ambitious and innovative study investigating new drugs that could potentially shorten treatment for tuberculosis — a goal that could make a huge difference for patients worldwide. Working on such a large, complex trial is like running a marathon: there are ups and downs along the way, but the collaboration within our Unit and with teams around the world keeps us moving forward. Everyone plays their part, and every small victory is worth celebrating as we work together toward something truly impactful.”
November 5, 2025 at 10:36 AM
mrcctu.bsky.social
Nominations for the Brighter Future Award (BFA) are still open!

This international award, organised by Penta Foundation (@pentafoundation.bsky.social), celebrates individuals making a meaningful impact in maternal and child health.

⏳ New deadline: 11 Nov
🔗 Nominate your hero: penta-id.org/bfa/
pentafoundation.bsky.social Penta Foundation @pentafoundation.bsky.social · 7d
Incredible nominations are already coming in for #BFA2025 & we can’t wait to celebrate more champions.

Our past Penta BFA winners prove that local heroes can change global health.

Entries close 15 November.

Nominate your hero today! www.penta-id.org/bfa
November 4, 2025 at 11:16 AM
mrcctu.bsky.social
Dr Sophie Merrick (@drsophiemerrick.bsky.social) presented at #ESMO25 results from her qualitative study within the RAMPART #ClinicalTrial.

Her research highlights how immunotherapy impacts the lives of kidney cancer patients, an essential view in cancer care.

🔗 View the poster: buff.ly/fPtvyZ2
A photo of Sophie standing in front of her poster at the ESMO conference 2025
November 3, 2025 at 11:34 AM
Reposted by MRC Clinical Trials Unit at UCL
hrb-tmrn.bsky.social
HRB-TMRN WEBINAR, with @mrcnihrtmrp.bsky.social - Prof. Max Parmar, Director of @mrcctu.bsky.social & UCL Institute of Clinical Trials, discusses 'Improving Health Faster: A more Strategic Approach to Randomised Trials & Meta-Analysis' on 20Nov@1pm(UTC): universityofgalway-ie.zoom.us/webinar/regi...
October 28, 2025 at 3:37 PM
mrcctu.bsky.social
It’s Wednesday, which means it’s time to celebrate another #ProudestOf moment from our amazing team at the Unit!

This week, we spotlight Tra My Pham, one of our dedicated senior Research Fellows working in analysis methodology.

We asked Tra what she’s #ProudestOf in her work at the Unit 👇
A card with a quote from Tra My Pham. It reads “I'm proud to have contributed to the ongoing development of clinical trial analysis methodology, helping to ensure optimal use of patient data to answer clinically relevant questions.”
October 29, 2025 at 8:47 AM
mrcctu.bsky.social
We're excited to share our latest work on estimands in clinical trials!

📄 Estimating treatment effects in trials with outcome data truncated by death: A case study on aligning estimators with estimands.

🔗 Read the full paper: journals.sagepub.com/doi/10.1177/...
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 27, 2025 at 2:42 PM
mrcctu.bsky.social
🎓 Thinking about a PhD in clinical trial #methodology?

We have two funded PhD opportunities for students passionate about trial design and statistical methods:

• One in estimands
• One in non-inferiority trials

🔗 More info and how to apply here: buff.ly/lCpqcF6

@mrcnihrtmrp.bsky.social
Current Opportunities
We have an iCASE studentship available to start for the 2025/2026 academic year, and applications to our fifth round of recruitment to our DTP to start in October 2026 are now also open. Please see…
buff.ly
October 23, 2025 at 9:02 AM
mrcctu.bsky.social
Let’s kick off Wednesday with another #ProudestOf moment from our amazing team at the Unit!

Today, we’re spotlighting Paul Hyams, our Facilities, Health and Safety Manager at ICTM.

We asked Paul what he’s #ProudestOf in his work at the Unit 👇
A card with a quote from Paul. It reads “I'm proud that, together with the well-being team, we're continuing to offer activities and support that help everyone at the Institute stay informed, trained, and looked after. Whether it's health and safety events, access to helpful resources, or having trained people to talk to, we're building a strong support system for mental, physical, and social wellbeing."
October 22, 2025 at 7:09 AM
mrcctu.bsky.social
📈 Exciting news from #ESMO25!

First results from the RAMPART trial show that a combination of 2 immunotherapy drugs (durvalumab and tremelimumab) helps prevent kidney cancer from coming back after surgery.

🔗 Read the full story: www.mrcctu.ucl.ac.uk/news/news-st...
A combination of two immunotherapy drugs benefits people with kidney cancer | MRC Clinical Trials Unit at UCL
www.mrcctu.ucl.ac.uk
October 21, 2025 at 8:15 AM
mrcctu.bsky.social
Over the weekend, we announced new findings from the ICON8B trial at #ESMO25.

Results show that weekly chemotherapy with bevacizumab improves survival of women with advanced #OvarianCancer compared to having it once every 3 weeks.

🔗Learn more on our website: www.mrcctu.ucl.ac.uk/news/news-st...
Weekly chemotherapy with bevacizumab improves ovarian cancer survival compared to having it once every three weeks | MRC Clinical Trials Unit at UCL
www.mrcctu.ucl.ac.uk
October 20, 2025 at 9:02 AM
mrcctu.bsky.social
🚨Big news in Parkinson’s research!

We are excited to share that the largest-ever Parkinson’s disease trial has launched across the UK. Using our multi-arm, multi-stage #MAMS design, the #ejsactpd trial aims to stop or slow the progression of the disease.

🔗 More www.mrcctu.ucl.ac.uk/news/news-st...
Largest-ever Parkinson’s disease trial opens across UK | MRC Clinical Trials Unit at UCL
www.mrcctu.ucl.ac.uk
October 16, 2025 at 9:30 AM
mrcctu.bsky.social
#ESMO25 is fast approaching…

If you are attending, check out the details of talks and posters featuring MRC CTU at UCL trials and meta-analysis work 👇
mrcctu.bsky.social MRC Clinical Trials Unit at UCL @mrcctu.bsky.social · Oct 6
Heading to #ESMO2025 in Berlin?

Make sure you catch the latest updates from our #ClinicalTrials in prostate, ovarian & kidney cancer, plus the STOPCAP meta-analysis.

Check out the full list of our posters & presentations in the image below 👇

@myesmo.bsky.social
Poster with the detailed schedule of presentations and posters from MRC CTU at UCL researchers at ESMO 2025.
October 15, 2025 at 9:22 AM
mrcctu.bsky.social
Wednesdays are our #ProudestOf days at the Unit!

This week, meet Berta Terre Torras, our Science Communications Officer and host of the #TrialTalk podcast.

We asked Berta what she’s #ProudestOf in his work at the Unit 👇
: A card with a quote from Berta. It reads “The thing I’m proudest of in my own work at the Unit is re-launching the Trial Talk podcast. Despite having no prior experience in podcasting, I embraced the challenge with the invaluable support of my team. Since then, we have produced two additional seasons, with 26 episodes that include discussions with more than 30 leading experts. These conversations have explored a wide range of topics - from groundbreaking clinical trial findings and innovative research methodologies to the critical role of PPI - bringing fresh insights to the forefront of clinical research.”
October 15, 2025 at 8:32 AM
mrcctu.bsky.social
To mark #BreastCancerAwarenessMonth, we are spotlighting the Add-Aspirin trial, which explores whether taking aspirin regularly after treatment could help stop breast cancer (and other cancers) from coming back.

🔗 Find out more about Add-Aspirin: www.mrcctu.ucl.ac.uk/studies/all-...
Add-Aspirin | MRC Clinical Trials Unit at UCL
www.mrcctu.ucl.ac.uk
October 14, 2025 at 8:22 AM
Reposted by MRC Clinical Trials Unit at UCL
mesamalaria.org
📊 Join this UCL @mrcctu.bsky.social Capacity Strengthening Hub webinar!

In collaboration with @lshtm.bsky.social 's ISEP team

🗓️ 13 Oct 2025 | ⏰ 10:00–11:30 UTC+1 | 💻 Online

🎙️ Speakers: Michelle Clements, Andrew Abaasa, Philip Ayieko, Vicky Simms

🔗 Register here: shorturl.at/hGtLq
October 10, 2025 at 10:40 AM
mrcctu.bsky.social
Let’s brighten up your Wednesday with another #ProudestOf moment from our brilliant team at the Unit!

This week, we’re spotlighting Yath Yogeswaran, one of our fantastic Research Fellows and a medical statistician on the STAMPEDE2 trial.

Here's what Yath is #ProudestOf from his work at the Unit 👇
A card with a quote from Yath. It reads “I’m proudest of being part of the STAMPEDE2 prostate cancer trial from the ground up - opening a trial is never easy, but seeing it launch, and patients recruited for treatment has been incredibly rewarding. What made this possible, and what I value most about our Unit, is its collaborative spirit, colleagues coming together, supporting one another, and sharing their expertise to make a real difference for patients."
October 8, 2025 at 9:44 AM
mrcctu.bsky.social
🏆 Nominations for the Penta Brighter Future Award are open!

Don’t miss the opportunity to celebrate inspiring contributions to maternal and child health worldwide with @pentafoundation.bsky.social

🔗 Nominate someone making a difference: penta-id.org/bfa/
October 7, 2025 at 7:55 AM
mrcctu.bsky.social
Heading to #ESMO2025 in Berlin?

Make sure you catch the latest updates from our #ClinicalTrials in prostate, ovarian & kidney cancer, plus the STOPCAP meta-analysis.

Check out the full list of our posters & presentations in the image below 👇

@myesmo.bsky.social
Poster with the detailed schedule of presentations and posters from MRC CTU at UCL researchers at ESMO 2025.
October 6, 2025 at 8:49 AM
mrcctu.bsky.social
Halfway through the week and full of pride… It’s time for another #ProudestOf moment!

This week, we’re spotlighting Gabriela Toledo, one of our brilliant Post-doctoral Research Fellows. She shares how building a supportive and friendly network has made all the difference in her work.
A card with a quote from Gabriela Toledo. It reads “The thing I am proudest of is the collaborative and welcoming community we’ve built among statisticians and doctoral students. Whether it’s socials, stats chats, or the MRC CTU at UCL’s bake off, it’s a genuinely supportive and fun environment that makes work more connected and enjoyable!”
October 1, 2025 at 9:48 AM
mrcctu.bsky.social
💻 Come along to our next Capacity Strengthening Hub webinar with @tghn-news.bsky.social on “How to be a good trial statistician”.

🗓️ 13 October 2025
🕙 10:00-11:30 BST
📍 Online (Zoom)

Register now: lnkd.in/e4RYCqNU
September 30, 2025 at 9:24 AM
mrcctu.bsky.social
It’s time for another #ProudestOf Wednesday!

Today, we’re spotlighting Matteo Quartagno (@matteoq21.bsky.social), Principal Research Fellow, who’s advancing the field with innovative trial designs as part of our #Methodology research.

Here’s what Matteo is #ProudestOf from his work at the Unit 👇
A card with a quote from Matteo Quartagno. It reads “I’m proud to have contributed to the development of innovative trial designs that reduce the burden on patients and healthcare systems while helping us identify better treatment strategies more efficiently. Approaches such as MAMS, PRACTical and ROCI have shown how trials can be more adaptive, resilient and impactful. What makes this even more rewarding is how receptive and engaged everyone involved in our trials – from clinicians and trial managers to data managers and research nurses – has been in embracing these innovations. Their commitment has turned methodology into practice, and I’m proud that together we are shaping research that will ultimately improve care for patients.”
September 24, 2025 at 9:08 AM
mrcctu.bsky.social
Continuing the legacy of #STAMPEDE in advancing #ProstateCancer care, we celebrate #UrologicalCancerAwarenessMonth by spotlighting STAMPEDE2.

This new trial explores 2 innovative treatments:
🔹 Targeted radiation
🔹 Nuclear medicine therapy
And plans to add some more.

🔗Learn more:
Home | Stampede2 Trial
buff.ly
September 18, 2025 at 11:02 AM
mrcctu.bsky.social
It’s Wednesday, which means it’s time for another #ProudestOf moment from our incredible team at the Unit!

This week, we spotlight Asiyya Tahsin, one of our fantastic research administrators and a member of our #PPI group.

We asked Asiyya what she’s #ProudestOf in her work at the Unit 👇
A card with a quote from Asiyya Tahsin. It reads “I’m most proud to have played a small role in supporting STAMPEDE, an astounding MAMS prostate cancer trial. Its adaptive design has since gained global popularity, inspiring similar trials worldwide. STAMPEDE was awarded the NIHR Impact Prize in March, a well-deserved recognition for a project that recruited nearly 12,000 patients and fast-tracked testing of 10 treatments in under two decades. Thanks to the patients and the dedicated team, STAMPEDE has influenced global treatment guidelines and changed clinical practice for prostate cancer multiple times. Its success has given rise to a new and exciting comeback, the STAMPEDE2 trial, which I’m also honoured to support.”
September 17, 2025 at 8:01 AM
mrcctu.bsky.social
To celebrate #UrologicalCancerAwarenessMonth, we look back at the many achievements of #STAMPEDE, the largest ever trial in advanced #ProstateCancer.

After 20 years and 12,000 participants, it has tested 10 different treatments and changed the standard-of-care 4 times.

Read more:
'25 at 25': Transforming prostate cancer treatment through the STAMPEDE clinical trial | MRC Clinical Trials Unit at UCL
12 Sep 2024
bit.ly
September 15, 2025 at 11:02 AM